MDCO News and Press, The Medicines Company From 11/21/19

With Alnylam Pharmaceuticals ( ALNY ) shares up almost 30% since my last update on the company, I can’t complain that the Street is undervaluing this RNAi pioneer nearly as much as before. Still, the company continues to build a strong investment case with two approvals in hand, ano...

Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Outperform rating and $128 (31% upside) price target at Oppenheimer. More news on: Alnylam Pharmaceuticals, Inc., Amarin Corporation plc, CytomX Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Shares of The Medicines Company (NASDAQ: MDCO) are up 18.6% at 12:19 p.m. EST after Bloomberg reported that the drugmaker had gotten interest from potential acquirers, including Novartis (NYSE: NVS) . A potential suitor would be after The Medicines Company's cholesterol-lowering drug inc...

Gainers:  SAExploration (NASDAQ: SAEX )  +85% . More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., Karuna Therapeutics, Inc., Stocks on the move, Read more ...

SAExploration Holdings (NASDAQ: SAEX ) +183%  on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...

Jeff: Joining me on the Stock Exchange is my colleague Todd E. Hurlbut, CMT, Chief Investment Officer at Incline Investment Advisors, LLC . Todd is the creator of the Emerald Bay model featured in this column. He is known as “Trending Todd.” And yes, that is a hint about his t...

Shares of The Medicines Company (NASDAQ: MDCO)  closed the trading day up 12.8% following the presentation of two phase 3 clinical trials testing cholesterol-lowering drug inclisiran at the American Heart Association's Scientific Sessions in Philadelphia. Shares of Alnylam Pharmaceutica...

Results from a Phase 3 clinical trial, ORION-9 , evaluating the effect of The Medicines Company's ( MDCO +2.3% ) inclisiran on reducing "bad" cholesterol (LDL-C) in patients with familial hypercholesterolemia (FH), an inherited condition characterized by abnormally high levels of chole...

- Inclisiran achieved 50% LDL-C lowering with time-adjusted reductions of 45% sustained over 18 months of treatment in patients with heterozygous familial hypercholesterolemia (HeFH) - ORION-9 further demonstrated inclisiran’s excellent safety profile, including no treatment-relate...

The Medicines Company (NASDAQ: MDCO ) is up  2%  premarket on light volume in reaction to positive results from a Phase 3 clinical trial, ORION-10 , evaluating inclisiran, dosed twice per year, in patients with atheroslerotic cardiovascular disease and elevated low-density lipop...